Advanced Enzyme Tech profit and loss

Latest FY26

Revenue: ₹746cr+17.1% on FY25
EBITDA: ₹229cr+17.8% on FY25
Net profit: ₹174cr+29.6% on FY25
EPS: ₹15.08+28.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	750	746	637	624	541	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	39.0	34.8	33.0	36.7	25.5
	789	781	670	661	566
	205	194	162	155	128
	0.0	0.0	0.0	0.0	0.0
	−12.3	−1.4	−10.1	−10.9	4.3
	167	162	142	128	115
	2.4	2.6	3.6	2.9	2.4
	40.4	40.1	36.6	35.2	35.0
	166	161	149	146	138
	569	559	483	458	422
	224	229	194	204	156
	183	189	158	169	121
Profit
	220	221	187	203	144
	11.4	11.4	0.0	−15.1	−4.1
	231	233	187	188	140
	56.0	56.4	49.5	56.2	42.9
	3.4	2.5	3.9	−5.3	−6.3
	59.4	58.9	53.4	50.9	36.5
	172	174	134	137	104
	172	174	134	137	104
	89.6	94.8	18.8	9.2	54.6
	261	268	153	146	158
	166	169	131	133	106
	5.9	4.9	2.9	3.6	−1.8
Per share
	₹14.82	₹15.08	₹11.72	₹11.92	₹9.45
	₹14.81	₹15.06	₹11.71	₹11.92	₹9.45
Other comprehensive income — detail
	89.6	94.8	18.8	—	—
	1.4	1.3	−0.7	−0.2	0.8
	0.4	0.3	−0.2	—	—
	—	—	—	−0.1	0.2
	88.6	93.8	19.3	9.4	54.0
	255	263	150	143	160
	5.9	5.0	2.9	3.6	−1.7
Per share — as-filed variants
	₹14.82	₹15.08	₹11.72	₹11.92	₹9.45
	₹14.81	₹15.06	₹11.71	₹11.92	₹9.45
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	557	553	485	479	409
	74.3%	74.1%	76.2%	76.8%	75.6%
Adjusted (ex-exceptional items) — derived
	220	221	187	203	144
	11.4	11.4	0.0	−15.1	−4.1
	163	165	134	148	107
	₹14.09	₹14.34	₹11.72	₹12.88	₹9.72

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

ADVENZYMES₹264.15

Advanced Enzyme Tech Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIPHARM AARTIDRUGS AGARWALEYE AKUMS ALIVUS APLLTD CORONA HCGMcap ₹2,956 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	540.6	623.9	636.9	745.8	749.6
Other Income	25.5	36.7	33.0	34.8	39.0
Total Income	566.1	660.5	670.0	780.6	788.6
Expenses
+ Cost of Materials Consumed	127.5	155.5	162.0	194.3	204.8
+ Purchases of Stock-in-Trade	0.0	0.0	0.0	0.0	0.0
+ Changes in Inventories	4.3	-10.9	-10.1	-1.4	-12.3
+ Employee Benefit Expense	114.8	128.4	141.5	162.3	167.1
+ Finance Costs	2.4	2.9	3.6	2.6	2.4
+ Depreciation & Amortisation	35.0	35.2	36.6	40.1	40.4
+ Other Expenses	137.6	146.5	149.1	161.5	166.3
Total Expenses	421.6	457.6	482.6	559.4	568.8
EBITDA	156.4	204.5	194.4	229.1	223.6
EBIT	121.4	169.2	157.9	189.0	183.2
Profit
PBT before Exceptional Items	144.5	203.0	187.4	221.2	219.8
+ Exceptional Items	-4.1	-15.1	0.0	11.4	11.4
Pretax Income	140.4	187.8	187.4	232.5	231.2
+ Current Tax	42.9	56.2	49.5	56.4	56.0
+ Deferred Tax	-6.3	-5.3	3.9	2.5	3.4
Tax Expense	36.5	50.9	53.4	58.9	59.4
Net Income	103.9	137.0	134.0	173.6	171.8
+ Net Income — Continuing Ops	103.9	137.0	134.0	173.6	171.8
+ Other Comprehensive Income	54.6	9.2	18.8	94.8	89.6
Total Comprehensive Income	158.5	146.2	152.8	268.4	261.4
Net Income to Common	105.6	133.3	131.1	168.7	165.9
Minority Interest	-1.8	3.6	2.9	4.9	5.9
Per Share
Basic EPS	9.45	11.92	11.72	15.08	14.82
Diluted EPS	9.45	11.92	11.71	15.06	14.81
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	18.8	94.8	89.6
+ Items NOT to be Reclassified to P&L	0.8	-0.2	-0.7	1.3	1.4
+ Tax on Items NOT to be Reclassified	—	—	-0.2	0.3	0.4
+ Tax on Items NOT to be Reclassified — alt tag	0.2	-0.1	—	—	—
+ Items to be Reclassified to P&L	54.0	9.4	19.3	93.8	88.6
Comprehensive Income — Owners of Parent	160.2	142.6	149.9	263.5	255.4
Comprehensive Income — Non-controlling Interests	-1.7	3.6	2.9	5.0	5.9
Per Share — as-filed variants
Basic EPS — Continuing Operations	9.45	11.92	11.72	15.08	14.82
Diluted EPS — Continuing Operations	9.45	11.92	11.71	15.06	14.81
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	408.8	479.3	485.0	552.8	557.0
Gross Margin %	75.62	76.83	76.16	74.13	74.31
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	144.5	203.0	187.4	221.2	219.8
− Exceptional Items (reconciliation)	-4.1	-15.1	0.0	11.4	11.4
Net Income Adj (tax-effected)	106.9	148.0	134.0	165.1	163.3
EPS Adj	9.72	12.88	11.72	14.34	14.09
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00
Filed Debt Equity	—	0.00	0.02	0.01	0.01
Filed Dscr	—	—	6.11	8.15	8.23
Filed Iscr	—	—	43.77	71.05	70.05
Paid Up Equity Capital	22.4	22.4	22.4	22.4	22.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.